CSPC's COVID-19 Vaccine Approved for Clinical Trials

On April 3, 2022, CSPC Pharmaceutical Group Co., Ltd. (Stock code 1093. HK) announced that the COVID-19 mRNA vaccine SYS6006 ("the product") developed by the Group was approved by the National Medical Products Administration for clinical trials in China.

SYS6006 is an mRNA vaccine independently developed by the Group to protect against the SARS-CoV-2 variant. The product is designed according to the prevalence of the strain, and preclinical studies have shown that the product exerts a good immunoprotective effect on the current major variants, including Omicron and Delta. It provides immunity for the human body through humoral immunity and cellular immunity, and can stimulate the production of memory B cells to provide a long-term protective effect. In addition, the preclinical safety evaluation data also fully prove the safety of the product.

The product adopts advanced manufacturing technology, with a highly controllable process, good batch-to-batch consistency, and easiness to scale up and industrialize. With good stability, it can be stored for a long time between 2-8 °C. The Group has achieved internalized production and domestic substitution of key raw materials and excipients for mRNA technology, which can meet the demand for large-scale supply.

Based on its advantages in safety, efficacy, and industrialization, and the need of epidemic prevention and control, the product has been included in the special approval procedure by the National Medical Products Administration and quickly approved for clinical trials.

The Group will make every effort to promote the domestic and international multi-center clinical trials of the product and strive to launch the product as soon as possible, so as to contribute to the global prevention and control of the COVID-19 epidemic.